Powered by: Motilal Oswal
2025-04-04 02:15:25 pm | Source: Accord Fintech
Pharma sector stocks tumble amid reports of imminent tariffs by Trump administration
Pharma sector stocks tumble amid reports of imminent tariffs by Trump administration

Pharmaceutical sector stocks slipped following reports that the Trump Administration will soon announce tariffs on pharma imports and emphasised that the measures will be ‘unprecedented’.

Aurobindo Pharma is currently trading at Rs. 1112.45, down by 63.60 points or 5.41% from its previous closing of Rs. 1176.05 on the BSE. The scrip opened at Rs. 1175.00 and has touched a high and low of Rs. 1176.60 and Rs. 1049.85 respectively. So far 140673 shares were traded on the counter.

Cipla is currently trading at Rs. 1415.25, down by 79.90 points or 5.34% from its previous closing of Rs. 1495.15 on the BSE. The scrip opened at Rs. 1499.25 and has touched a high and low of Rs. 1499.25 and Rs. 1390.35 respectively. So far 40021 shares were traded on the counter. 

Lupin is currently trading at Rs. 1977.75, down by 116.75 points or 5.57% from its previous closing of Rs. 2094.50 on the BSE. The scrip opened at Rs. 2094.35 and has touched a high and low of Rs. 2094.35 and Rs. 1918.20 respectively. So far 51714 shares were traded on the counter.

Sun Pharmaceutical Industries is currently trading at Rs. 1709.00, down by 61.10 points or 3.45% from its previous closing of Rs. 1770.10 on the BSE. The scrip opened at Rs. 1772.10 and has touched a high and low of Rs. 1781.70 and Rs. 1658.00 respectively. So far 88049 shares were traded on the counter.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here